A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

Objective: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1, capecitabine plus lapatinib, and trastuzumab plus...

Full description

Bibliographic Details
Main Authors: Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Breast
Subjects:
Breast cancer
Neoplasm metastasis
Cost-effectiveness analysis
Markov chains
Taiwan
Online Access:http://www.sciencedirect.com/science/article/pii/S096097761931104X

Internet

http://www.sciencedirect.com/science/article/pii/S096097761931104X

Similar Items